Plasma Proteome Profiling of a Mouse Model of Breast Cancer Identifies a Set of Up-regulated Proteins in Common with Human Breast Cancer Cells
Overview
Authors
Affiliations
We have applied an in-depth quantitative proteomic approach, combining isotopic labeling extensive intact protein separation and mass spectrometry, for high confidence identification of protein changes in plasmas from a mouse model of breast cancer. We hypothesized that a wide spectrum of proteins may be up-regulated in plasma with tumor development and that comparisons with proteins expressed in human breast cancer cell lines may identify a subset of up-regulated proteins in common with proteins expressed in breast cancer cell lines that may represent candidate biomarkers for breast cancer. Plasma from PyMT transgenic tumor-bearing mice and matched controls were obtained at two time points during tumor growth. A total of 133 proteins were found to be increased by 1.5-fold or greater at one or both time points. A comparison of this set of proteins with published findings from proteomic analysis of human breast cancer cell lines yielded 49 proteins with increased levels in mouse plasma that were identified in breast cancer cell lines. Pathway analysis comparing the subset of up-regulated proteins known to be expressed in breast cancer cell lines with other up-regulated proteins indicated a cancer related function for the former and a host-response function for the latter. We conclude that integration of proteomic findings from mouse models of breast cancer and from human breast cancer cell lines may help identify a subset of proteins released by breast cancer cells into the circulation and that occur at increased levels in breast cancer.
Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy.
Zivalj M, Van Ginderachter J, Stijlemans B Cancers (Basel). 2023; 15(21).
PMID: 37958332 PMC: 10648573. DOI: 10.3390/cancers15215159.
An Inflection Point in Cancer Protein Biomarkers: What was and What's Next.
Barker A, Alba M, Mallick P, Agus D, Lee J Mol Cell Proteomics. 2023; 22(7):100569.
PMID: 37196763 PMC: 10388583. DOI: 10.1016/j.mcpro.2023.100569.
Proteomics and its applications in breast cancer.
Neagu A, Whitham D, Buonanno E, Jenkins A, Alexa-Stratulat T, Tamba B Am J Cancer Res. 2021; 11(9):4006-4049.
PMID: 34659875 PMC: 8493401.
Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue.
Espin R, Baiges A, Blommaert E, Herranz C, Roman A, Saez B Mol Cancer Res. 2021; 19(11):1840-1853.
PMID: 34312290 PMC: 8568632. DOI: 10.1158/1541-7786.MCR-21-0220.
Fahrmann J, Vykoukal J, Fleury A, Tripathi S, Dennison J, Murage E J Natl Cancer Inst. 2019; 112(6):607-616.
PMID: 31503278 PMC: 7301069. DOI: 10.1093/jnci/djz182.